Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy for Lung Cancer: protocol for a multicenter, double-blind and randomized controlled trial

Jian-Guo Zhou; Pei-Jie Li; Su-Han Jin; Da-Hai Liu; Lang Huang; Ming-Ze Cao; Yu Zou; Hu Ma

doi:10.1101/19012583

Abstract

Background Chemotherapy-induced nausea and vomiting (CINV) is frequently observed after the administration of chemotherapy and significantly influences the quality of life (QoL) of patients. Olanzapine has a high control rate of CINV in patients with cancer when combined with the NK-1 receptor antagonist dexamethasone and 5-hydroxytryptamine (5-HT3) receptor antagonists. The efficacy of a regimen without an NK-1 receptor antagonist remains unknown. Therefore, we designed this randomized trial to provide evidence for the management of CINV.

Methods and ananlysis This is a double-blind, multicenter and randomized controlled trial. Patients with histologically confirmed lung cancer will be assessed by physicians based on the inclusion and exclusion criteria, and 156 participants will be enrolled and randomized to a placebo group or experiment group to receive treatment for CINV. The primary endpoint is the incidence of delayed CINV. The secondary endpoints are complete response (CR) of acute CINV, CR of delayed CINV, effective control rate (ECR) of CINV and QoL. During the six days after administration, these endpoints will be evaluated and recorded by physicians.

Ethic and dissemination This study has received approval from the institutional ethical review board of the Affiliated Hospital of Zunyi Medical University (ref approval No. 58). Written informed consent will be signed by all participants prior to enrolling. Participants will be randomly assigned to the experimental group or comparator group by blocked randomization.

Article summary Strengths and limitations

This study will provide evidence for physicians to find an affordable and effective treatment regimen for CINV through this study.
Because of the variety of pharmaceutical companies, medical care and other factors, problem of cost will be further explored in the following studies.
Although the study is designed as a double-blind randomized controlled trial, QoL will be measured by a questionnaire that is filled out by patients themselves. This may influence the conclusions.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT03571126.

Funding Statement

This trial is conducted with no external funding and is instead funded from the Qian Ke He (2019) 4440 and the Special Fund for Traditional Chinese Medicine and Ethnic Medicine supported by the Administration of Traditional Chinese Medicine of Guizhou Province (grant QZYY2017-113). Project ZY-201751044 is supported by Zunyi Medical University Training Program of Innovation and Entrepreneurship for Undergraduates. Project ZYKY-20173830 is supported by Zunyi Medical University School of Medicine and Science Training Program of Innovation and Entrepreneurship for Undergraduates, the Open Project Program of the Special Key Laboratory of Oral Diseases Research, the Higher Education Institution in Guizhou Province, and the Master Scientific Research Foundation of Zunyi Medical University.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes